SOTALOL/GENERICS 80MG/TAB TAB Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

sotalol/generics 80mg/tab tab

generics pharma hellas ΕΠΕ - sotalol - ΔΙΣΚΙΟ - 80mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

SOTALOL/GENERICS 160MG/TAB TAB Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

sotalol/generics 160mg/tab tab

generics pharma hellas ΕΠΕ - sotalol - ΔΙΣΚΙΟ - 160mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

PENTAXIM POWDER & SUSPENSION FOR SUSPENSION FOR INJECTION Siprus - Yunani - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

pentaxim powder & suspension for suspension for injection

sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - diphtheria toxoid; poliomyelitis virus type 3; tetanus toxoid; pertussis toxoid(pt); filamentous haemagglutinin (fha); poliomyelitis virus type 2; poliomyelitis virus type 1; haemophilus infl. type b polys.conj.t.toxoid - powder & suspension for suspension for injection - diphtheria toxoid (8000000804) 0iu; poliomyelitis virus type 3 (8000000485) 32du; tetanus toxoid (8000040440) 0iu; pertussis toxoid(pt) (8000001811) 25mcg; filamentous haemagglutinin (fha) (8000001813) 25mcg; poliomyelitis virus type 2 (8000000484) 8du; poliomyelitis virus type 1 (8000000483) 40du; haemophilus infl. type b polys.conj.t.toxoid (8000001810) 10mcg - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Ultomiris Uni Eropa - Yunani - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - Αιμοσφαιρινουρία, παροξυσμική - Επιλεκτικά ανοσοκατασταλτικά - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

AVAXIM 160 ANTIGEN UNITS/0.5ML SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE Siprus - Yunani - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

avaxim 160 antigen units/0.5ml suspension for injection in pre-filled syringe

sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - hepatitis a virus (gbm strain) inactivated - suspension for injection in pre-filled syringe - 160 antigen units/0.5ml - hepatitis a virus (gbm strain) inactivated (8000003025) 160u - hepatitis a, inactivated, whole virus

VIGAM LIQUID 5G/100ML SOLUTION FOR INTRAVENOUS INFUSION Siprus - Yunani - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

vigam liquid 5g/100ml solution for intravenous infusion

bio products laboratory limited (0000009242) dagger lane, elstree, hertfordshire, wd6 3bx - immunoglobulin human normal - solution for intravenous infusion - 5g/100ml - immunoglobulin human normal (8000012671) 5% w/v - immunoglobulins, normal human, for intravasc. adm.